Human thymus activation regulated chemokine,TARC ELISA Kit

Code CSB-E09257h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
chemokine (C-C motif) ligand 17
Alternative Names
A-152E5.3 ELISA Kit; A152E53 ELISA Kit; ABCD 2 ELISA Kit; ABCD2 ELISA Kit; C-C motif chemokine 17 ELISA Kit; CC chemokine TARC ELISA Kit; CCL17 ELISA Kit; CCL17_HUMAN ELISA Kit; Chemokine CC Motif Ligand 17 ELISA Kit; MGC138271 ELISA Kit; MGC138273 ELISA Kit; SCYA17 ELISA Kit; Small Inducible Cytokine A17 ELISA Kit; Small Inducible Cytokine A17 Precursor ELISA Kit; Small Inducible Cytokine Subfamily A (Cys Cys) ELISA Kit; Small Inducible Cytokine Subfamily A (Cys Cys) Member 17 ELISA Kit; Small-inducible cytokine A17 ELISA Kit; T Cell Directed CC Chemokine ELISA Kit; Thymus and activation regulated chemokine ELISA Kit; Thymus and activation-regulated chemokine ELISA Kit
Abbreviation
CCL17
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
15.6 pg/mL-1000 pg/mL
Sensitivity
3.9 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Immunology
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human TARC in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:5 Average % 106
Range % 101-115
1:10 Average % 104
Range % 102-108
1:20 Average % 87
Range % 84-93
1:40 Average % 94
Range % 90-97
Recovery
The recovery of human TARC spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 96 90-101
EDTA plasma (n=4) 89 85-92
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected
1000 2.455 2.655 2.555 2.385
500 2.015 2.101 2.058 1.888
250 1.323 1.333 1.328 1.158
125 0.738 0.802 0.770 0.600
62.5 0.420 0.453 0.437 0.267
31.2 0.288 0.282 0.285 0.115
15.6 0.213 0.218 0.216 0.046
0 0.169 0.171 0.170  
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This human TARC ELISA kit employs the quantitative sandwich enzyme immunoassay technique to measure the levels of human TARC in multiple samples, including serum, plasma, or tissue homogenates. It also uses the enzyme-substrate chromogenic reaction to visualize and analyze the analyte levels through the color intensity. The intensity of the colored product is in direct proportion to the TARC levels in the sample and is measured at 450 nm through a microplate reader.

TARC, also called CCL17, is constitutively expressed in the thymus and produced by dendritic cells (DCs), endothelial cells, keratinocytes, and bronchial epithelial cells. CCL17 plays an important role in T cell development in the thymus, and it binds to CCR4 and displays chemotactic activity for T lymphocytes, predominantly Th2 cells. Moreover, some studies have demonstrated that chemokine CCL17, an important regulator of atherosclerosis, is positively related to coronary artery disease, independent of traditional cardiovascular risk factors. Another study has revealed that circulating CCL17 plays a crucial role in aging as well as Ang II-induced pathological cardiac remodeling and heart failure (HF).

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Chemotactic factor for T-lymphocytes but not monocytes or granulocytes. May play a role in T-cell development in thymus and in trafficking and activation of mature T-cells. Binds to CCR4.
Gene References into Functions
  1. The frequency of the CC genotype in the TARC rs223828 SNP was higher in patients with intractable Graves disease than in patients with Graves disease in remission. PMID: 29848886
  2. The expression of CCL17 was decreased in nasal polyp (NP) epithelium compared to the epithelium of normal ethmoid sinus, whereas the expression of CCL22 was not decreased. E-cadherin was differentially distributed between the epithelium of normal ethmoid sinus and NP epithelium. EGFR was also decreased in NPs. PMID: 29746583
  3. TARC serum levels were elevated in 78% of sarcoidosis patients and correlated with disease severity. PMID: 29598931
  4. Serum TARC level may be a potent marker reflecting better response to IL-17A inhibitors for psoriasis treatment. PMID: 29655215
  5. This review presents key clinical studies of Multiple sclerosis together with experimental studies in animals that have demonstrated functional roles of CCR4, CCL17, and CCL22 in experimental autoimmune encephalomyelitis pathogenesis. [review] PMID: 29099057
  6. Taken together, our data showed a likely positive feedback mechanism of enhanced IL-6 production in ectopic milieu. The high levels of IL-6 in the peritoneal cavity stimulate the expression of CCL17 in endometrial stromal cells by activating JNK signal pathway, and then, CCL17 further induces CCR4 expression on macrophages, which eventually leads to an increase in IL-6 production via NF-kappaB activation. PMID: 28240436
  7. Data suggest that high levels of CCL17 and CCL22 in endometrium in women with endometriosis promote (1) recruitment of Tregs, (2) immunosuppression of Tregs, and (3) angiogenesis in endometrium. (Tregs = regulatory T cells) PMID: 28383711
  8. Serum TARC levels correlate well with indicators of systemic inflammation and of disease severity among patients with a drug eruption except SJS/TEN. Serum TARC may be a prognostic biomarker of severity of inflammation in drug eruptions. PMID: 28648978
  9. TARC production in HaCaT keratinocytes through the interaction between IL-22 and IL-22Ralpha facilitates T-cell migration in atopic dermatitis caused by house dust mites. PMID: 26914146
  10. TARC is a candidate biomarker for PTSD only in males. PMID: 28170001
  11. High CCL17 expression is associated with colon cancer cell migration. PMID: 28146427
  12. GM-CSF can mediate inflammation and pain by regulating IRF4-induced CCL17 production PMID: 27525438
  13. Based on the ADEPT study data set, we report that airway mucosal expression of CCL26 was a robust discriminator of type 2 inflammation from healthy nonatopic subjects. Furthermore, airway mucosal CCL26 expression was best identified by using a panel of clinical biomarkers, including Feno values, bEOS counts, and expression of 2 novel markers, sCCL17 and sCCL26 PMID: 28089872
  14. Low CCL17 expression is a potential independent adverse prognostic biomarker for recurrence and survival of patients with clear cell renal cell carcinoma after nephrectomy. PMID: 28178948
  15. IP-10 serum increase or TARC/IP-10 ratio decrease along with abnormal hepatic enzymatic alteration could signify early rejection of the transplanted liver. PMID: 28245475
  16. elevated pre-treatment levels of sGal-1, sCD163, sCD30 and TARC can be found in patients with classic Hodgkin lymphoma. However, only plasma TARC accurately reflects disease activity and correlates with clinical treatment response. PMID: 27610595
  17. levels elevated in rheumatoid arthritis synovial fluid, due to production by mononuclear cells, particularly CD1c classical dendritic cells PMID: 27250804
  18. Serum TARC levels are well correlated with blood eosinophil counts in patients with generalized drug eruptions, indicating that Th2-type immune reactions underlie TARC production. Serum TARC measurements also have potent diagnostic value for DIHS, with high sensitivity and specificity. PMID: 27497618
  19. Data suggest that Th1 (IFN-gamma-inducible protein-10 IP-10/CXCL10) and Th2 (thymus and activation regulated chemokine TARC/CCL17) and (macrophage derived chemokine MDC/CCL22) cooperatively play a role in the development of ankylosing spondylitis (AS). PMID: 26827189
  20. CCL17 positively regulates the tumorigenesis of hepatocellular carcinoma.Higher levels of intratumoral CCL17 expression are associated with poorer survival of hepatocellular carcinoma patients. PMID: 26781124
  21. CCL17 and CCL18 dermal expression is associated with leprosy polarity. PMID: 25412496
  22. The SNP rs223895 in TARC/CCL17 gene is associated with the susceptibility to Kawasaki disease. PMID: 26182268
  23. Serum CCL17 levels are associated with coronary artery disease and atherosclerosis severity independently of traditional cardiovascular risk factors. PMID: 25555269
  24. TARC was correlated with disease status and its monitoring may be able to predict PET positivity after alloSCT, thus potentially allowing an early immune manipulation. PMID: 25240818
  25. Serum levels of CCL17 were positively correlated with coronary artery disease. PMID: 25062565
  26. increased expression in the thymus of myasthenia gravis patients PMID: 24397961
  27. TARC and interleukin-31 may be biomarkers for adult atopic dermatitis PMID: 24984931
  28. Serum TARC is a promising biomarker for remission and can be used for accurately monitoring proactive treatment for long-term control. [revew] PMID: 24628072
  29. disease activity and response biomarker in alopecia areata PMID: 24102731
  30. High CXCL10 levels were detected in acutely infected children regardless of virus pathogen, whereas increased CCL17 production was RSV-specific PMID: 25013801
  31. Higher serum concentrations of CCL17 at baseline may be predictive of acute exacerbations in patients with chronic hypersensitivity pneumonitis PMID: 23705860
  32. might be potential marker of non-eosinophilic oesophagitis gastrointestinal food allergies PMID: 24698291
  33. Serum TARC may represent a suitable biomarker for monitoring of atopic dermatitis severity in daily practice. PMID: 25199679
  34. Although TARC and I-TAC may not directly regulate pruritus in atopic dermatitis patients, these chemokines are very sensitive disease markers of AD. PMID: 24104601
  35. we found that TARC is an easily measured biomarker that is associated with faster TTR, longer PFS, and possibly longer OS in a population of patients with HL who were treated with panobinostat. PMID: 23822537
  36. The serum TARC level is a very sensitive biomarker for monitoring the severity and treatment response in AD PMID: 25268342
  37. CCL17 is an antimicrobial protein with bacteriocidal activity against E. coli and S. aureus. PMID: 12949249
  38. An association between TARC/CCL17 polymorphisms, susceptibility of Kawasaki disease, and intravenous immunoglobulin responses in Kawasaki disease patients. PMID: 23942559
  39. Migration assays were performed to evaluate CCL17-induced colon cancer cell (HT-29) chemotaxis and RhoA protein levels were quantified. PMID: 24582560
  40. Ginseng inhibited TARC expression via blockade of NF-kappaB activation in HaCaT cells. PMID: 23454147
  41. CCL17-induced, CCR4-dependent release of CGRP by human airway epithelial cells represents a novel inflammatory pathway in patients with asthma and allergic disease. PMID: 23731651
  42. These data reveal an elevated serum concentration of Th2-attracting chemokines CCL22 and CCL17 in opsoclonus-myoclonus syndrome. PMID: 23340773
  43. Autistic children had significantly higher serum levels of TARC than healthy controls PMID: 23782855
  44. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. PMID: 23224400
  45. Data suggest an important role for serum CCL17 level as biomarker of drug resistance/remission induction in Hodgkin lymphoma in response to various combined neoplastic agent protocols. PMID: 23225085
  46. increased expression in macrophages from asthmatic patients PMID: 22981793
  47. Data show that PD-1, PD-L1, PD-L2, CCL17, and CCL22 mRNA was identified in papillomas. PMID: 22322668
  48. Serum concentrations of TARC and CTACK were significantly higher in AD (atopic dermatitis) children than in healthy controls, and correlated with severity of symptoms. PMID: 22017510
  49. Baseline plasma thymus and activation-regulated chemokine levels correlate with classical Hodgkin's lymphoma tumor burden and serial levels correlate with response to treatment in patients with classical Hodgkin's lymphoma. PMID: 22058214
  50. PI16-positive Treg showed enhanced in vitro migration towards the inflammatory chemokines CCL17 and CCL20, suggesting they can migrate to sites of inflammation PMID: 22533972

Show More

Hide All

Subcellular Location
Secreted.
Protein Families
Intercrine beta (chemokine CC) family
Tissue Specificity
Expressed at high levels in thymus and at low levels in the lung, colon and small intestine.
Database Links

HGNC: 10615

OMIM: 601520

KEGG: hsa:6361

STRING: 9606.ENSP00000219244

UniGene: Hs.546294

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X